Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

9 results about "Kidney stone disease" patented technology

Kidney stone disease, also known as urolithiasis, is when a solid piece of material (kidney stone) develops in the urinary tract. Kidney stones typically form in the kidney and leave the body in the urine stream. A small stone may pass without causing symptoms. If a stone grows to more than 5 millimeters (0.2 in), it can cause blockage of the ureter, resulting in severe pain in the lower back or abdomen. A stone may also result in blood in the urine, vomiting, or painful urination. About half of people who have had a kidney stone will have another within ten years.

Lactobacillus johnsonii strain od-5, its uses and products

PendingCN122445539AStone formationBacilli
The application discloses a lactobacillus johnsonii OD-5 and application and products thereof, and belongs to the technical field of microorganisms. A technical problem to be solved by the application is to provide a lactobacillus johnsonii capable of treating kidney stones. A technical solution is a lactobacillus johnsonii OD-5 with a preservation number of CGMCC No. 38426. The lactobacillus johnsonii can reduce urine oxalic acid and regulate urine calcium, effectively correct abnormal urine biochemical conditions promoting stone formation, reduce related kidney function damage, and inhibit formation and deposition of calcium oxalate crystals in the kidney at a histopathological level, thereby significantly reducing the stone incidence. The application provides a solid theoretical basis for development of products taking the lactobacillus johnsonii OD-5 as a core component and used for preventing kidney stones and improving stone kidney damage.
Owner:ZHONGKE WISBIOM(BEIJING)BIOTECHNOLOGY CO LTD

Method for preparing heterocyclic derivative compound, composition containing same compound, and hydrate of same compound

PendingUS20260070923A1Organic active ingredientsAntipyreticDiseaseChronic renal insufficiency
The present invention relates to: a novel method for preparing a heterocyclic derivative compound of chemical formula I below; a novel intermediate compound used in the preparation method; a composition for treatment or prevention of hyperuricacidemia, gout, nephritis, chronic renal insufficiency, nephrolith, uremia, urolithiasis, or a uric acid-related disease, the composition containing the compound of chemical formula I at a dose of more than 2 mg and equal to or less than 10 mg and being orally administered once a day; and a hydrochloride 1.5 hydrate of the novel compound of chemical formula I.
Owner:JW PHARMA CORP

Ergothioneine, S-methyl-ergothioneine, and uses thereof

The present invention provides S-methyl-L-ergothioneine for use in diagnosis and / or prognosis. The invention also provides a method for the diagnosis and / or prognosis of a renal disease comprising the step of determining the amount of S-methyl-L-ergothioneine in an isolated test sample of a subject, and methods for deciding or recommending whether to initiate a therapeutic intervention or for determining the efficacy of a therapeutic intervention. It is also herein provided ergothioneine for use in the treatment and / or prevention of a renal lithiasis or an aminoaciduria, and ergothioneine for use in combination therapy.
Owner:FUNDACIO INSTITUT D INVESTIGACIO BIOMEDICA DE BELLVITGE (IDIBELL) +2

Bifidobacterium animalis lactis ro-1, products and uses thereof

PendingCN122445538ABiotechnologyRenal Tubule Epithelium
The application discloses an animal bifidobacterium lactis subsp. RO-1 and products and applications thereof, and belongs to the technical field of microorganisms. The technical problem to be solved is to provide an animal bifidobacterium lactis subsp. capable of preventing the formation and recurrence of kidney stones. The technical solution is to provide an animal bifidobacterium lactis subsp. RO-1, and the preservation number is CGMCC No. 38427. The animal bifidobacterium lactis subsp. RO-1 can regulate urine stone-related indexes, down-regulate urine oxalic acid and urine calcium-related creatinine ratio, weaken the generation inducement of calcium oxalate crystals, reduce urea nitrogen and urine protein creatinine ratio, improve glomerular filtration capacity, reduce nitrogen waste accumulation and protein leakage, reduce the damage of a kidney filtration barrier, repair the structural integrity of a renal tubule, and significantly reduce the kidney stone formation rate.
Owner:ZHONGKE WISBIOM(BEIJING)BIOTECHNOLOGY CO LTD

A traditional Chinese medicine composition for treating calculus

ActiveCN116509977BDigestive systemFungi medical ingredientsCyathula officinalisBile Juice
The present application relates to a kind of traditional Chinese medicine composition for treating calculus, raw material is: walnut kernel 25-35 parts, black fungus 10-20 parts, giant knotweed 15-25 parts, powder 25-35 parts of yam, sea gold sand 25-35 parts, 10-20 parts of yujin, 25-35 parts of huashi grass, 25-35 parts of shaddock, 10-20 parts of goose tube stone, 25-35 parts of yiwren, 10-20 parts of magnolia officinalis, 25-35 parts of xuanming powder, 10-20 parts of rhubarb, 10-20 parts of plantago, 10-20 parts of bupleurum, 10-20 parts of small chrysanthemum, 5-10 parts of cumin, 10-20 parts of Sichuan donkey's hide, 5-10 parts of raw licorice.The present application has the effect of clearing heat and promoting bile secretion, dissolving stone and stopping bleeding cooling blood, through the concept of dissolving stone and expelling stone, large stone is small, small stone is small, gallstones are discharged with bile into intestine, kidney stones, ureter and bladder stones are discharged with urine, adjust liver, gallbladder, kidney and other qi stagnation, and be supplemented with constitution conditioning syndrome differentiation treatment, it has good curative effect on various stones of liver, gallbladder, kidney and urinary tract, and it is both the treatment of principle and secondary, relieve the suffering of the majority of patients.
Owner:李学刚

Plant-derived compound oral liquid for promoting post-operation residual calculus discharge and application of plant-derived compound oral liquid

The invention provides a plant-derived compound oral liquid for promoting post-operation residual calculus discharge and application thereof.The oral liquid takes orthosiphon aristatus, lygodium japonicum, lysimachia christinae hance and other plants as core raw materials, the core raw materials are compounded with vaccinium myrtillus extract and globe artichoke extract, and an intestinal flora regulator composed of xylooligosaccharide and inactivated lactobacillus plantarum is added; the natural sweetening agent and the thickening stabilizer are matched; meanwhile, the purification and extraction process of the extract and the preparation flow of oral liquid reflux extraction, compound blending and sterilization filling are optimized. All the components cooperate to achieve the multi-dimensional effects of stone dissolving, excretion promoting, urinary tract mucosa repairing and intestinal flora adjusting, the postoperative residual stone excretion rate can be remarkably increased, urinary tract inflammation is relieved, and the stone recurrence risk is reduced; the pharmaceutical composition is stable and controllable in preparation process, high in dissolution rate of effective components, free of chemical synthesis additives and good in safety, can be widely applied to preparation of drugs for promoting discharge of residual calculi after kidney calculi, urethral calculi and cystolith operations, and is remarkable in clinical application value.
Owner:HAIKOU THIRD PEOPLES HOSPITAL

Application of hydroxysafflor yellow A

The invention discloses an application of hydroxysafflor yellow A. Experiments prove that the hydroxysafflor yellow A can prevent / treat kidney stone, so that the hydroxysafflor yellow A can be used in related fields of drugs for treating kidney stone, drugs for preventing kidney stone formation and the like, and a new drug and a new treatment thought are provided for treating or preventing calcium oxalate kidney stone diseases. The invention provides a novel therapeutic drug for preventing and / or treating and / or relieving calculi in mammals such as cats and dogs.
Owner:ZHONGKE TIANHE (TIANJIN) BIOTECHNOLOGY CO LTD +1

Ergothioneine, S-methyl-ergothioneine and their uses

ActiveKR102992657B1DiseaseTest sample
The present invention provides S-methyl-L-ergothioneine for use in diagnosis and / or prognosis. The present invention also provides a method for diagnosing and / or prognosing renal disease comprising the step of determining the amount of S-methyl-L-ergothioneine in an isolated test sample of a subject, and a method for determining or recommending whether to initiate a therapeutic intervention or determining the efficacy of a therapeutic intervention. Additionally, the invention provides ergothioneine for use in the treatment and / or prevention of renal calculosis or aminoaciduria, and ergothioneine for use in combination therapy.
Owner:FUNDACIO INSTITUT D INVESTIGACIO BIOMEDICA DE BELLVITGE (IDIBELL) +2

Complementary herbal medicine for the treatment of oxalate kidney stones, urinary tract infections, and sexual dysfunctions

PCT designated stageWO2026087943A1Organic active ingredientsUrinary disorderComplementary medicineSexual function
The present invention relates to a complementary herbal composition for the treatment of oxalate kidney stones, urinary tract infections (UTIs), and sexual dysfunctions. The composition comprises a synergistic blend of herbal ingredients, including Rumex obstusifolius, Lessertia frutescens, Hypoxis hemerocallidea, Gunnera perpensa, Achillea millefolium, Echinacea purpurea, Taraxacum officinale, Epimedium sagittatum, and Rosa canina L., in specific quantities. The formulation is administered in a water base and preserved with Potassium sorbate. PHYTOCASD offers natural, multi-targeted therapeutic benefits, including dissolving oxalate kidney stones, preventing and treating UTIs, and improving sexual function. The invention is intended for use as a complementary medicine, leveraging the diuretic, antimicrobial, anti-inflammatory, and aphrodisiac properties of its ingredients to provide a comprehensive and safe treatment option for individuals suffering from these conditions.
Owner:SEOTSANYANA THABANG D